Skip to Content
  • Previous Rank401
  • Revenues ($M)7,670
  • Revenue Percent Change18.1%
  • Profits ($M)2,000
  • Profits Percent Change37.9%
  • Market Value (as of March 31, 2015)92,292

The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multimple myeloma, inflammatory diseases, and various forms of cancer.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

CEO
Mark J. Alles
Industry
Pharmaceuticals
Sector
Health Care
HQ Location
Summit, NJ
Websitehttp://www.celgene.com
Years on List4

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)7,67018.1%
Profits ($M)2,00037.9%
Total Stockholder Equity6,525-
Employees6,012-
Market Value (as of March 31, 2015)92,292-

Profit Ratios

Profit as % of Revenues26.1%
Profits as % of Assets11.5%
Profits as % of Stockholder Equity30.7%

Earnings Per Share (last fiscal year)

Earnings Per Share ($)2.39
EPS % Change (from 2013)41.8%
EPS % Change (5 year annual rate)23.6%
EPS % Change (10 year annual rate)40.9%

Total Return

Total Return to Investors (2014)32.4%
Total Return to Investors (5 year, annualized)32.1%
Total Return to Investors (10 year, annualized)32.7%